Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report)'s share price shot up 3.1% during trading on Thursday . The company traded as high as $7.28 and last traded at $7.21. 21,443 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 61,265 shares. The stock had previously closed at $6.99.
Analyst Upgrades and Downgrades
A number of research firms recently commented on AVTX. Wedbush began coverage on Avalo Therapeutics in a research note on Friday. They issued an "outperform" rating and a $18.00 price objective on the stock. BTIG Research began coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 price objective on the stock. Finally, HC Wainwright began coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They issued a "neutral" rating on the stock.
View Our Latest Stock Report on Avalo Therapeutics
Avalo Therapeutics Trading Up 17.9 %
The company has a fifty day moving average of $7.82 and a 200-day moving average of $9.40.
Institutional Investors Weigh In On Avalo Therapeutics
Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its stake in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in Avalo Therapeutics in the 4th quarter valued at $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics in the 4th quarter valued at $145,000. Northern Trust Corp bought a new position in Avalo Therapeutics in the 4th quarter valued at $168,000. Finally, Bank of Montreal Can bought a new position in Avalo Therapeutics in the 4th quarter valued at $446,000. Institutional investors own 87.06% of the company's stock.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Read More
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
